Pharvaris N.V. (FRA:9EN)

Germany flag Germany · Delayed Price · Currency is EUR
24.00
-1.20 (-4.76%)
At close: Dec 4, 2025
28.34%
Market Cap 1.54B
Revenue (ttm) n/a
Net Income (ttm) -163.72M
Shares Out n/a
EPS (ttm) -2.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 19
Open 24.80
Previous Close 25.20
Day's Range 24.00 - 24.80
52-Week Range 10.20 - 25.20
Beta n/a
RSI 59.05
Earnings Date Nov 20, 2025

About Pharvaris

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; a... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 108
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 9EN
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.